tissue growth factor (CTGF) and myofibroblast alpha smooth muscle actin (α-SMA) protein production by Western blot as well as immunofluorescence and validated at the mRNA level by Quantitative PCR. Activation of the TGF-β pathway was determined by measuring the TGF-β receptor 1 (ALK5) and phosphorylated Smad2/3 levels by using Western blot and immunofluorescence. Luciferase assay was used to measure nAG protein's capacity to inhibit the thee TGF-β isomers. Cell migration was assessed using a scratch assay and finally colocalization of nAG protein with TGF-β receptor 1 was evaluated using confocal microscopy.
RESULTS:
Both the Western Blot and the immunofluorescence results revealed that the application of the nAG protein to human scleroderma fibroblasts in the presence of TGF-β successfully inhibited the fibrotic response shown by a decrease in the fibrotic factors such as collagen III, alpha smooth muscle actin (α-SMA), connective tissue growth factor (CTGF) and fibronectin. In addition, immunofluorescence and western blot after 1 hour of treatment with nAG revealed a significant decrease in Phosphorylated Smad2/3, and a decrease in the TGF-β receptor 1 (ALK5) inhibiting the TGF-β pathway. Luciferase assay revealed nAG's inhibition of the canonical TGF-β pathway to be most specific with TGF-β1 isomer reducing activity by 83%. Cell migration was significantly inhibited with nAG protein treatment and confocal microscopy revealed the colocalization of nAG protein with ALK5 receptors.
CONCLUSION: Fibrosis in scleroderma fibroblasts was effectively inhibited when treated with nAG protein, demonstrated by the decrease in ECM using Western Blot and immunofluorescence. Although much about the mechanism of the nAG protein is still unknown, the decrease in pSmad2/3 and ALK5 receptors most potently with TGF-β1 after treatment, inhibition of cell migration and binding of nAG protein with ALK5 receptors suggest that nAG blocks the canonical TGF-β pathway. This research is anticipated to lead to the development of an injectable antifibrotic agent for the treatment of fibrotic disorders such as scleroderma, hypertrophic scars and keloids. PURPOSE: Arteriovenous malformation (AVM) is a locally destructive congenital vascular anomaly that enlarges over time. We previously reported that AVMs contain somatic mutations in the MAP2K1 gene, and that the mutation is isolated to the endothelial cell (EC). The purpose of this study was to determine the effects of MAP2K1 mutations in ECs on its signaling pathway.
METHODS:
Human AVM-ECs were collected during a clinically-indicated procedure. MAP2K1 mutations (K57N) were confirmed in the ECs using droplet digital PCR (ddPCR). We also engineered wild-type endothelial colony forming cells (ECFCs) with the MAP2K1 (K57N) mutation. Patient-derived MAP2K1-AVM ECs and engineered MAP2K1-ECFCs were compared to control ECs: human white adipose (HWAT-ECs), ECFCs + empty vector, and ECFCs + wild-type MAP2K1 vector. Western blot analysis was used to assess cell signaling along the RAS/MAPK pathway (e.g., baseline and phosphorylated MEK1 and ERK1/2). Densitometry quantification was performed with Image Studio™ Lite (Version 5.2).
RESULTS:
Human MAP2K1-AVM ECs had consistent baseline MEK1 and ERK1/2 expression with controls; however, MAP2K1-AVM ECs produced 176% more active/phosphorylated ERK1/2 than non-mutant ECs. Similarly, ECFCs engineered to overexpress mutant MAP2K1 demonstrated 433% more phosphorylated ERK1/2 expression than control ECFCs.
CONCLUSIONS: MAP2K1 mutations in both humanderived AVM ECs as well as in engineered ECs activate the RAS/MAPK signaling pathway by increasing phosphorylation of ERK1/2, which is the downstream target of MAP2K1. Pharmacotherapy that inhibits the activating function of the mutation may inhibit the growth of AVMs. 
